SBIO - ETF AI Analysis
Top Page
ALPS Medical Breakthroughs ETF (SBIO)
SBIO’s rating reflects a mix of promising medical breakthrough companies alongside the high risks typical of early-stage biotech. Stronger holdings like ACADIA Pharmaceuticals, with solid finances, positive earnings sentiment, and clear growth plans, help support the fund’s quality, while weaker, pre-revenue names such as Oruka Therapeutics and Edgewise Therapeutics, which face ongoing losses and bearish trading signals, weigh on the overall score. The main risk factor is SBIO’s heavy concentration in small, clinical-stage biotech firms that depend on successful trial outcomes and external funding, making the ETF more volatile and speculative.
SBIO vs. SPDR S&P 500 ETF (SPY)
- AUM
- 187.80M
- Region
- North America
- Expense Ratio
- 0.50%
- Beta
- 1.16
- Issuer
- ALPS
- Inception Date
- Dec 31, 2014
- Dividend Yield
- 2.14%
- Asset Class
- Equity
- Index Tracked
- S-Network Medical Breakthroughs Index
SBIO Summary
SBIO is the ALPS Medical Breakthroughs ETF, which follows the S-Network Medical Breakthroughs Index and focuses on smaller U.S. biotech companies working on new drugs and treatments, especially those in later-stage clinical trials. It holds many developing names, including firms like Travere Therapeutics and Amylyx Pharmaceuticals. Someone might invest in SBIO for the chance at higher growth by backing cutting-edge medical innovations and to get targeted exposure to the health care and biotech theme. A key risk is that these early-stage biotech stocks can be very volatile and may rise or fall sharply based on drug trial results and market sentiment.
How much will it cost me?
This ETF has an expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 you invest. That’s higher than the average ETF because it focuses on a specialized, actively selected group of small and mid-sized biotech companies, which typically cost more to manage.
What would affect this ETF?
Future performance of this U.S.-focused biotech ETF will be helped by strong demand for new drugs, supportive health care regulations, and successful trial results from its many small and mid-sized companies developing breakthrough therapies. On the downside, setbacks in clinical trials, tighter drug pricing rules, or rising interest rates that make it harder for these smaller firms to raise money could hurt the ETF’s returns.
SBIO Top 10 Holdings
SBIO is a pure play on U.S. small- and mid-cap biotech, so individual drug stories drive the show. Oruka Therapeutics and Veradermics have been rising lately, giving the fund some welcome lift as investors warm to their late-stage pipelines. Relay Therapeutics and Amylyx look steadier, helping to balance out the bumps typical in this space. On the downside, CG Oncology, Travere, and Xenon have been lagging, acting like a weight on the portfolio as trial setbacks and funding worries cool sentiment. Overall, it’s a concentrated bet on breakthrough medicine with plenty of volatility baked in.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ORKA | Oruka Therapeutics | 4.27% | $7.86M | $6.41B | 244.61% | 41Neutral |
 MANE | Veradermics, Incorporated | 3.88% | $7.15M | $5.84B | 270.04% | ―― |
 CGON | CG Oncology, Inc. | 3.82% | $7.02M | $5.73B | 52.30% | 58Neutral |
 DFTX | Definium Therapeutics | 3.25% | $5.98M | $4.88B | 171.32% | 40Neutral |
 TVTX | Travere Therapeutics | 3.16% | $5.82M | $4.75B | 69.95% | 56Neutral |
 DNTH | Dianthus Therapeutics | 3.07% | $5.64M | $4.61B | 144.16% | 61Neutral |
 EWTX | Edgewise Therapeutics | 2.81% | $5.17M | $4.22B | 108.36% | 40Underperform |
 RLAY | Relay Therapeutics | 2.68% | $4.92M | $4.02B | 150.00% | 59Neutral |
 AMLX | Amylyx Pharmaceuticals Inc | 2.41% | $4.44M | $3.62B | 105.41% | 52Neutral |
 XENE | Xenon | 2.41% | $4.44M | $3.62B | -12.33% | 48Neutral |
SBIO Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SBIO, the sentiment is Negative. The current price of 54.87 is above the 20-day moving average (MA) of 53.92, below the 50-day MA of 59.83, and below the 200-day MA of 57.05, indicating a neutral trend. The MACD of -1.08 indicates Negative momentum. The RSI at 46.05 is Neutral, neither overbought nor oversold. The STOCH value of 78.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBIO.
SBIO Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| SBIO | $54.87 | $54.00(-1.59% Downside) | $187.80M | 0.50% | 46Neutral |
 RSPH | $39.69 | $42.47(6.99% Upside) | $991.68M | 0.40% | 71Outperform |
 PJP | $130.54 | $158.86(21.69% Upside) | $575.09M | 0.58% | 70Neutral |
 XPH | $64.80 | $109.12(68.40% Upside) | $466.58M | 0.35% | 56Neutral |
 PBE | $102.50 | $125.38(22.32% Upside) | $445.63M | 0.59% | 70Outperform |
 BBP | $104.18 | $151.92(45.82% Upside) | $136.83M | 0.34% | 60Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SBIO | ALPS Medical Breakthroughs ETF | 54.87 | 10.92 | 24.84% | |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 39.69 | 9.65 | 32.11% | |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 130.54 | 34.57 | 36.02% | |
| XPH | SPDR S&P Pharmaceuticals ETF | 64.80 | 15.34 | 31.00% | |
| PBE | Invesco Dynamic Biotechnology & Genome ETF | 102.50 | 29.00 | 39.46% | |
| BBP | Virtus LifeSci Biotech Products ETF | 104.18 | 30.44 | 41.29% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.